PIRe 2.0: A Stepped-Care Model for Involving Relatives Across Sectors
NCT07590726 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 160
Last updated 2026-05-19
Summary
Serious brain diseases and injuries affect not only the person who becomes ill or injured, but also their family. Relatives of people with acquired brain injury (ABI) or malignant brain tumor (MBT) often take on a major role in daily care, decision-making, and coordination across healthcare services. This role can include managing information, supporting rehabilitation, and acting as a link between hospital care and community rehabilitation. Many relatives report high levels of stress, uncertainty, and emotional burden, especially during transitions between care settings.
Despite recommendations for greater involvement of relatives, support for this group is often uneven and poorly coordinated across healthcare sectors. Relatives frequently experience lack of overview, limited guidance, and unclear expectations regarding their role. These challenges may increase caregiver burden and negatively affect both relatives' well-being and the continuity of care.
The PIRe 2.0 study aims to further test, and implement a structured intervention to support systematic involvement of relatives of people with ABI or MBT across hospital and community rehabilitation services. The intervention is designed as a "caregiver compass" that helps relatives understand their role, clarify their needs and wishes for involvement, and gain better overview of the care pathway.
PIRe 2.0 is delivered through a stepped-care model, which allows the level of support to be adjusted over time based on each relative's level of burden and support needs. All relatives receive basic information and screening for caregiver burden using the 4-item Zarit Burden Interview (ZBI-4). Relatives who show signs of increased burden are offered additional support in steps, ranging from structured conversations with nurses to extended cross-sector coordination and specialized support for relatives with high or complex needs. Decisions about stepping up or down are based on both screening results and clinical assessment to ensure flexibility and person-centered care.
The study includes two groups of relatives: an intervention group receiving support through the PIRe stepped-care model, and a control group receiving usual care only. A total of 160 relatives will participate. Data are collected at baseline, at transitions between hospital and community care, and three to six months after the intervention.
The primary outcome is change in caregiver burden, measured with the Caregiver Burden Scale (CBS). Secondary outcomes include relatives' roles and responsibilities, perceived support and involvement in care, and mental well-being, assessed using validated patient-reported outcome measures.
In addition to evaluating the effect of the intervention, the study examines how the PIRe model can be implemented and sustained in everyday practice across healthcare sectors. The results are expected to show whether a structured, stepped-care approach can reduce caregiver burden, improve coordination between hospital and community services, and support more coherent and secure care pathways for people with ABI or malignant brain tumor and their relatives.
Conditions
- Brain Injuries, Acute
- Brain Tumor Adult
- Brain (Nervous System) Cancers
- Traumatic Brain Injuries
- Glioblastom WHO Grade 4
- Glioblastoma (GBM)
- Stroke
Interventions
- OTHER
-
Supportive Care
The intervention uses a stepped-care model to support relatives based on their level of burden and support needs. All participants receive basic support, and additional support is offered step-by-step when needed. Step 1 - Usual Care and Screening All relatives receive usual care and basic information. Caregiver burden is screened using the 4-item Zarit Burden Interview (ZBI-4). Step 2 - Structured Support Relatives who screen positive on the ZBI-4 are offered a structured PIRe conversation with a nurse. The conversation focuses on the relative's role, needs, and wishes for involvement, as well as providing better overview of the care pathway. Step 3 - Extended Support Relatives with increased burden, based on ZBI-4 results and clinical assessment, receive extended and more targeted support, including follow-up conversations and improved coordination between hospital and community services. Step 4 - Specialized Support Relatives with high burden or complex needs receive specialized sup
Sponsors & Collaborators
-
Rigshospitalet, Denmark
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-10-01
- Primary Completion
- 2027-04-01
- Completion
- 2029-09-30
Countries
- Denmark
Study Locations
More Related Trials
-
Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors
NCT01151670 ·Status: COMPLETED ·Phase: PHASE1
-
PET-Guided Resection in High-Grade Gliomas
NCT07567196 ·Status: RECRUITING
-
Nivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade Glioma
NCT04267146 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Feasibility of Individualized, Model-guided Optimization of Proton Beam Treatment Planning in Patients With Low Grade Glioma
NCT05964569 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluation of the Incidence of NTRK Gene Fusion in Adult Brain Tumours
NCT05025969 ·Status: COMPLETED
-
Image Guided Reirradiation of High-grade Glioma
NCT02025231 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Low Dose Radiation Therapy for Glioblastoma Multiforme
NCT01466686 ·Status: COMPLETED ·Phase: PHASE2
-
Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide
NCT00616005 ·Status: COMPLETED ·Phase: PHASE2
-
Hypofractionated Stereotactic Radiotherapy for Patients With Recurrent High Grade Glioma
NCT02567539 ·Status: COMPLETED ·Phase: NA
-
Cognitive Outcome After Gamma Knife Radiosurgery in Patients With Brain Metastases (CAR-Study A)
NCT02953756 ·Status: COMPLETED
-
Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
NCT03212742 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
NCT00114140 ·Status: COMPLETED ·Phase: PHASE2
-
Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma
NCT01305122 ·Status: TERMINATED ·Phase: NA
-
Radiation Therapy or Combination Chemotherapy in Treating Patients With Clinically or Radiologically Progressive Low-Grade Gliomas
NCT00276640 ·Status: COMPLETED ·Phase: NA
-
Image-derived Prediction of Response to Chemo-radiation in Glioblastoma
NCT02329795 ·Status: TERMINATED
-
A Pilot Study to Evaluate Neurocognitive Injury and Longitudinal Changes in White Matter During Radiation Therapy in Children With Primary Brain Tumors
NCT02006407 ·Status: TERMINATED ·Phase: NA
-
Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
NCT02709226 ·Status: COMPLETED ·Phase: PHASE1
-
Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.
NCT07439172 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Seizures During Radiotherapy for High-grade Gliomas
NCT04552756 ·Status: TERMINATED ·Phase: NA
-
MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma
NCT00756106 ·Status: TERMINATED ·Phase: NA
-
Temozolomide in Elderly Patients With KPS < 70
NCT01242566 ·Status: COMPLETED ·Phase: PHASE2
-
Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline
NCT06779487 ·Status: RECRUITING
-
Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients
NCT02850744 ·Status: TERMINATED ·Phase: PHASE2
-
Re-TREAT: Re-irradiation for Relapsed Brain Metastases
NCT05126875 ·Status: UNKNOWN ·Phase: NA
-
Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery
NCT01417507 ·Status: COMPLETED